Liposomal phosphodiester, phosphorothioate, and p-ethoxy...

Details Liposomal phosphodiester, phosphorothioate, and p-ethoxy... Liposomal phosphodiester, phosphorothioate, and p-ethoxy...

2007-02-13

2007-02-13

Schultz, James (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C514S04400A, C435S006120, C435S325000, C435S375000

Reexamination Certificate

active

10462172

ABSTRACT:
An improved delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is selected from the group consisting of phosphodiester oligonucleotides, phosphorothioate oligonucleotides, and p-ethoxy oligonucleotides.

REFERENCES:
patent: 4229360 (1980-10-01), Schneider et al.
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4480041 (1984-10-01), Myles et al.
patent: 4721612 (1988-01-01), Janoff et al.
patent: 4835263 (1989-05-01), Nguyen et al.
patent: 4837028 (1989-06-01), Allen
patent: 4904582 (1990-02-01), Tullis
patent: 4920016 (1990-04-01), Allen et al.
patent: 4924624 (1990-05-01), Suhadolnik et al.
patent: 4950432 (1990-08-01), Mehta et al.
patent: 5030442 (1991-07-01), Uster et al.
patent: 5049388 (1991-09-01), Knight et al.
patent: 5087617 (1992-02-01), Smith
patent: 5094785 (1992-03-01), Law et al.
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5100662 (1992-03-01), Bolcsak et al.
patent: 5112962 (1992-05-01), Letsinger et al.
patent: 5135917 (1992-08-01), Burch
patent: 5178875 (1993-01-01), Lenk et al.
patent: 5188897 (1993-02-01), Suhadolnik et al.
patent: 5202429 (1993-04-01), Tsujimoto et al.
patent: 5227170 (1993-07-01), Sullivan
patent: 5248671 (1993-09-01), Smith
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5271941 (1993-12-01), Cho-Chung
patent: 5279833 (1994-01-01), Rose
patent: 5279957 (1994-01-01), Gross
patent: 5320962 (1994-06-01), Stiles et al.
patent: 5324654 (1994-06-01), Bredesen
patent: 5376646 (1994-12-01), Pittrof et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5417978 (1995-05-01), Tari et al.
patent: 5525719 (1996-06-01), Srivasta and Raza
patent: 5527538 (1996-06-01), Baldeschwieler
patent: 5560923 (1996-10-01), Rahman et al.
patent: 5661018 (1997-08-01), Ashley et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5696248 (1997-12-01), Peyman et al.
patent: 5705385 (1998-01-01), Bally et al.
patent: 5734033 (1998-03-01), Reed
patent: 5750669 (1998-05-01), Rosch et al.
patent: 5756122 (1998-05-01), Thierry et al.
patent: 5817811 (1998-10-01), Breipohl et al.
patent: 5831048 (1998-11-01), Schweighoffer et al.
patent: 5831066 (1998-11-01), Reed
patent: 5855911 (1999-01-01), Lopez-Berestein et al.
patent: 5874224 (1999-02-01), Bandman et al.
patent: 5874553 (1999-02-01), Peyman et al.
patent: 5891714 (1999-04-01), Ashley et al.
patent: 5908635 (1999-06-01), Thierry
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 6015886 (2000-01-01), Dale et al.
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 6040181 (2000-03-01), Reed
patent: 6042846 (2000-03-01), Lopez-Berestein et al.
patent: 6096720 (2000-08-01), Love et al.
patent: 6110490 (2000-08-01), Thierry
patent: 6120794 (2000-09-01), Liu et al.
patent: 6120798 (2000-09-01), Allen et al.
patent: 6126965 (2000-10-01), Kasid et al.
patent: 6136965 (2000-10-01), Bruice et al.
patent: 6211162 (2001-04-01), Dale et al.
patent: 6211349 (2001-04-01), Dale et al.
patent: 6277832 (2001-08-01), Sugiyama et al.
patent: 6277981 (2001-08-01), Tu et al.
patent: 6291668 (2001-09-01), Ziegler et al.
patent: 6326487 (2001-12-01), Peyman et al.
patent: 6414134 (2002-07-01), Reed
patent: 2171589 (1996-03-01), None
patent: 4110085 (1991-03-01), None
patent: WO 88/04924 (1988-07-01), None
patent: WO 89/06977 (1989-08-01), None
patent: WO 90/09180 (1990-08-01), None
patent: WO 90/10488 (1990-09-01), None
patent: WO 91/16901 (1991-11-01), None
patent: WO 92/21330 (1992-12-01), None
patent: WO 92/22303 (1992-12-01), None
patent: WO 93/07883 (1993-04-01), None
patent: WO 93/11245 (1993-06-01), None
patent: WO 93/24640 (1993-12-01), None
patent: WO 94/04545 (1994-03-01), None
patent: WO 94/05259 (1994-03-01), None
patent: WO 95/03788 (1995-02-01), None
patent: WO 96/27663 (1996-09-01), None
patent: WO 96/40062 (1996-12-01), None
patent: WO 00/40595 (2000-07-01), None
Uhlmann et al. Chemical Reviews 1990, v90(4) 545-579.
Agrwal, “Antisense oligonucleotides; torwards clinical trials,”TIBTECH, 14:376-387, 1996.
Agris et al., “Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonucleoside methylposphonates,”Biochemistry, 25:6268-6275, 1986.
Akhtar et al., “Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes),”Nucleic Acids Research, 19(20): 5551-5559, 1991.
Akhtar et al., “Liposome delivery of antisense methylphosphonate and phosphorothioate oligonucleotides: A study with MLV, FATMLV, and LUV liposomes,”Proceed Intern. Symp. Control. Rel. Bioact. Mater., 19:345-346, 1992.
Akhtar et al. “Release of antisense oligdeoxynucleotide analogues from liposomes: implications for cellular transport and drug delivery,” 128th Meeting of British Pharmaceutical Conference 1991, United Kingdom, Sep. 10-13, 1991,J. Pharm. Pharmacol., 43 (Suppl.):Abstract 24P, 1991.
Arad et al., “Use of reconstituted sendai virus envelopes for fusion-mediated microinjection of double-stranded RNA: Inhibition of protein synthesis in interferon-treated cells,”Biochimica et Biophysica Acta, 859:88-94, 1986.
Bakhshi et al., “Cloning the Chromosomal Breakpoint of t(14;18) Human Lymphomas: Clustering around JHon Chromosome 14 and near a Transcriptional Unit on 18,”Cell, 41:899, 1985.
Bennett et al., “Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides,”Molecular Pharmacology, 41(6):1023-1033, 1992.
Boiziau et al., “Modified oligonucleotides in rabbit reticulocytes: uptake, stability and antisense properties,” Biochimie, 73:1403-1408, 1991.
Branch, A., “A good antisense molecule is hard to find,”TIBS, 23:45-49, 1998.
Budker et al., “Cell membranes as barriers for antisense construction,”Antisense Research and Development, 2:177-184, 1992.
Capaccioli et al., “Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum,”Biochemical and Biophysical Research Communications, 197(2):818-825, 1993.
Citro et al., “Chemical modification of ligands for cell receptors to introduce foreign compounds into the cells,”Colon&Rectum, 37(2):S127-S132, 1994.
Clarenc et al., “Delivery of antisense oligonucleotides by poly(l-lysine) conjugation and liposome encapsulation,”Anti-Cancer Drug Design, 8:81-94, 1993.
Cotter et al., “Antisense oligonucleotides supress B-cell lymphoma growth in a SCID-hu mouse model.”Oncogene, 9:3-49-3055, 1994.
Gerwirtz et al., “Facilitating oligonucleotide delivery: helping antisense delivery on its promise,”Proc. Natl. Acad. Sci U.S.A., 93: 3161-3163, 1996.
Gura, “Antisense has growing pains,”Science, 270:575-577, 1995.
Juliano et al., “Liposomes as a drug delivery system for antisense oligonucleotides,”Antisense Research and Development2:165-176, 1992.
Keller et al., “Synthesis and hybridization properties of oligonucleotides containing 2′-O-modified ribonucleotides,”Nucleic Acids Research, 21(19):4499-4505, 1993.
Krieg et al., “Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesteryl moiety increases cellular association and improves efficacy,”Proc. Natl. Acad. Sci., USA, 90:1048-1052, 1993.
Kramer et al., “Self-specific T lymphocyte lines as vehicles for gene therapy: myelin specific T cells carrying exogenous nerve growth factor gene (abstract),”J. Cell. Biochem., Suppl. o (17 Part E):215, 1993.
Leonetti et al., “Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication,”Proc. Natl. Acad. Sci. USA, 87:2448-2451, 1990.
Loke et al., “Delivery of c-mycantisense oligodeoxynucleotides to hematopoieti

Affiliated with

Also associated with

Rating

Liposomal phosphodiester, phosphorothioate, and p-ethoxy... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Liposomal phosphodiester, phosphorothioate, and p-ethoxy..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal phosphodiester, phosphorothioate, and p-ethoxy... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3893331